Name
CergenX
What We Do (Printed Profile Company Description)
CergenX presents Wave, an FDA Breakthrough Designated device that uses AI to deliver rapid, expert-level brain assessments in newborns. With just 10 minutes of raw 2-channel EEG, Wave detects abnormal activity, including seizures, to identify infants at increased risk of neonatal encephalopathy - no specialist skills required.
Powered by the CergenX AI Platform, Wave combines multiple clinical-grade models, including our neonatal seizure detection algorithm published in npj Digital Medicine (2025) - the first globally to match human expert performance. Built for scale, our platform continuously advances through data, AI, and clinical deployment.
Visit Booth 938 to learn more, explore our ongoing studies, and see Wave in action.
Powered by the CergenX AI Platform, Wave combines multiple clinical-grade models, including our neonatal seizure detection algorithm published in npj Digital Medicine (2025) - the first globally to match human expert performance. Built for scale, our platform continuously advances through data, AI, and clinical deployment.
Visit Booth 938 to learn more, explore our ongoing studies, and see Wave in action.
Website
Categories
Clinical Tools, Diagnostics, EEG Systems, Medical Device, Other, Research Ad, Seizure Detection, Software
Address
Dublin,
Ireland
Ireland
Twitter